The prevalence of COVID-19 infections among patients with mastocytosis is similar to that found in patients with chronic myeloid leukemia (CML) and in the general Austrian population, according to a new study published in the European Journal of Haematology.

Most (66.3%) patients included in the study had indolent systemic mastocytosis (SM).

“Together, our data demonstrate that the risk of a Covid-19 infection in patients with mastocytosis or CML does not differ comparing to the general Austrian population,” the authors said. “The characteristics of the patients with mastocytosis and Covid-19 infections are similar to those of the general population.”

The occurrence of COVID-19 infections in patients with mastocytosis was 2.2%, whereas in patients with CML, it was 5.3%. One-quarter of patients with mastocytosis presented signs and symptoms of infection such as fever (n=11), dry cough (n=10), sore throat (n=12), pneumonia (n=1), and dyspnea (n=3). However, only 2 symptomatic patients tested positive for COVID-19 with a polymerase chain reaction test. Both patients were female and aged above 50 years. None required hospital admission but 1 of them suffered from post-COVID-19 syndrome.

Read more about SM epidemiology

The study enrolled 92 patients with different types of mastocytosis, including indolent SM (n=61), mastocytosis in the skin (n=11), systemic mastocytosis with an associated hematologic neoplasm (n=7), cutaneous mastocytosis (n=6), smoldering systemic mastocytosis (n=4), and aggressive systemic mastocytosis (n=3). Moreover, 113 patients with CML, as well as the expected prevalence of COVID-19 in the general Austrian population, were used as controls.


Graf I, Herndlhofer S, Kundi M, et al. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: a comparison with the general Austrian population. Eur J Haematol. Published online October 4, 2022. doi: